These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Verheijen JH; Rijken DC; Chang GT; Preston FE; Kluft C Thromb Haemost; 1984 Jul; 51(3):396-7. PubMed ID: 6437007 [TBL] [Abstract][Full Text] [Related]
3. [Is hypofibrinolysis a risk factor of thrombosis?]. Juhan-Vague I Rev Prat; 1989 Nov; 39(26):2337-9. PubMed ID: 2512628 [No Abstract] [Full Text] [Related]
4. Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. Nilsson T; Mellbring G; Hedner U Acta Chir Scand; 1986 May; 152():347-9. PubMed ID: 3090810 [TBL] [Abstract][Full Text] [Related]
5. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies. Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090 [TBL] [Abstract][Full Text] [Related]
6. [Current developments in fibrinolytic therapy]. Rijken DC Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567 [No Abstract] [Full Text] [Related]
7. [Actual and reserve fibrinolytic activity in the postoperative period--possibility of exhaustion of the reserve of vascular plasminogen activator]. Psuja P; Sowier J; Gizło J; Zawilska K Acta Haematol Pol; 1980; 11(1):1-7. PubMed ID: 7189316 [No Abstract] [Full Text] [Related]
8. [Short-acting fibrinolysis in the etiology of venous thrombosis]. Petäjä J; Myllylä G; Rasi V; Vahtera E Duodecim; 1988; 104(5):317-24. PubMed ID: 3139389 [No Abstract] [Full Text] [Related]
9. The role of the fibrinolytic system in thrombotic disease. Wiman B Acta Med Scand Suppl; 1987; 715():169-71. PubMed ID: 3109214 [No Abstract] [Full Text] [Related]
12. [Fibrinolytic system of the skin: localization and modulation of plasminogen activator (PA) and PA inhibitor]. Izaki S; Hibino T Rinsho Ketsueki; 1987 Jul; 28(7):1127-33. PubMed ID: 3121894 [No Abstract] [Full Text] [Related]
13. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin). Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871 [TBL] [Abstract][Full Text] [Related]
14. Altered fibrinolysis in DVT: influence of site of sampling. Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091 [TBL] [Abstract][Full Text] [Related]
15. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Loskutoff DJ Semin Thromb Hemost; 1988 Jan; 14(1):100-9. PubMed ID: 3127883 [No Abstract] [Full Text] [Related]
18. [Molecular markers of hemostatic mechanisms--interaction of plasminogen activator and its inhibitor]. Sakata Y Rinsho Byori; 1989 Mar; 37(3):256-60. PubMed ID: 2787424 [No Abstract] [Full Text] [Related]
19. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)]. Félez J; Rueda F Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250 [No Abstract] [Full Text] [Related]
20. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]